


## AZD5462

Cat. No.:	HY-148087		
CAS No.:	2787501-83-9		
Molecular Formula:	C <sub>30</sub> H <sub>41</sub> FN <sub>2</sub> O <sub>6</sub>		
Molecular Weight:	544.65		
Target:	RXFP Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (183.60 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.8360 mL	9.1802 mL	18.3604 mL
	5 mM	0.3672 mL	1.8360 mL	3.6721 mL
	10 mM	0.1836 mL	0.9180 mL	1.8360 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (4.59 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (4.59 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (4.59 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

AZD5462 is a RXFP1 modulator, can be used for heart failure research. RXFP1 is the cognate receptor for human relaxin, belongs to GPCR family 1c number with anti-fibrotic and anti-inflammatory properties<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

RXFP1<sup>[1]</sup>

#### In Vitro

AZD5462 (example 1) shows stimulatory activity on cAMP or cGMP production with EC<sub>50</sub>s of 17 nM and 50 nM, respectively<sup>[1]</sup>. AZD5462 binds human plasma protein with fraction unbound (free) rate of 4.3%, and shows the stability with Cl<sub>int</sub> values of 23 μL/min/mg (human liver microsomal), 4.8 μL/min/10<sup>6</sup> cells (human hepatocyte), and 11 μL/min/10<sup>6</sup> cells (rat hepatocyte)

---

[1].

AZD5462 enhances phosphorylation of ERK with an EC<sub>50</sub> value of 6.3 nM<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Granberg Kenneth Lars, et al. 4-(2-Fluoro-4-methoxy-5-(3-(((1-methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as RXFP1 modulators for the treatment of heart failure and their preparation: World Intellectual Property Organization, WO2022122773. 2022-06-16.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA